Medical Journals

Canine Visceral Leishmaniosis: a Comparative Analysis of the Eie-leishmaniose-visceral-canina-bio-manguinhos and the Ifi-leishmaniose-visceral-canina-bio-manguinhos Kits.

Authors:
  • Lira R A
  • Cavalcanti M Paiva
  • Nakazawa M
  • Ferreira A G P
  • Silva E D
  • Abath F G C
  • Alves L C
  • Souza W V
  • Gomes Y M

From: Departamento de Imunologia, Centro de Pesquisas Aggeu Magalhães/CPqAM, Fundação Oswaldo Cruz/FIOCRUZ, Av. Moraes Rego s/n, Cidade Universitária, 50670-420, Recife-PE, Brazil.

Veterinary parasitology

  • Publish Date: Apr 2006
  • ISSN: 0304-4017
  • Volume: 137
  • Issue: 1-2
  • Pages: 11-6
  • Medium: Print
  • Language: English
  • Citation (JAMA): Lira R A, Cavalcanti M Paiva, Nakazawa M, et al. Canine Visceral Leishmaniosis: a Comparative Analysis of the Eie-leishmaniose-visceral-canina-bio-manguinhos and the Ifi-leishmaniose-visceral-canina-bio-manguinhos Kits.. Vet. Parasitol. Apr 2006;137:11-6

Abstract

This study evaluated the performance of the EIE-leishmaniose-visceral-canina-Bio-Manguinhos (EIE-LVC) kit and to compare it with that of the IFI-leishmaniose-visceral-canina-Bio-Manguinhos (IFI-LVC) kit. Four groups of dogs were studied: group 1 (G1), dogs with clinical signs indicative of CVL and testing positive for the parasite (n = 25); group 2 (G2), dogs with only a presumed diagnosis of CVL (n = 62); group 3 (G3), dogs that had never lived in an area where CVL is endemic and never received a blood transfusion (n = 16); group 4 (G4), dogs carrying other parasites: such as babesiosis (n = 4), ehrlichiosis (n = 6) and demodicosis (n = 1). G1 and G3 were used for the calculation of sensitivity and specificity, respectively. The EIE-LVC showed a sensitivity of 72% (IC 95%: 50.4-87.1%) and a specificity of 87.5% (IC 95%: 60.4-97.8%). The value of the kappa index was 0.975 (CI 95%: 0.926-1.024), which represents an excellent fit. For IFI-LVC, the sensitivity was 68.0% (CI 95%: 46.4-84.3%) and the specificity 87.5% (CI 95%: 60.4-97.8%). When the tests were conducted in parallel, sensitivity was 92.0% (CI 95%: 72.5-98.6%) and specificity 75.0% (CI 95%: 47.4-91.7%). However, when conducted consecutively, the tests showed a sensitivity of 48.0% (CI 95%: 28.3-68.2%) and a specificity of 100.0% (CI 95%: 75.9-99.4%). The analysis of clinically suspected dogs using IFI-LVC and EIE-LVC kits in parallel, revealed that 26/62 animals were positive. Cross-reaction was observed in a dog with demodicosis. These results lead to the following conclusions: (1) the performance of the EIE-LVC kit is not statistically different from the IFI-LVC and (2) the kits must be used in parallel if higher sensitivity is required, reducing the number of false-negative results.

Mesh Headings (Keywords): Animals, Antibodies, Protozoan, Antigens, Protozoan, Case-Control Studies, Cross Reactions, Dog Diseases, Dogs, Enzyme-Linked Immunosorbent Assay, False Negative Reactions, Immunoenzyme Techniques, Leishmania donovani, Leishmaniasis, Visceral, Reagent Kits, Diagnostic, Recombinant Proteins, Reproducibility of Results, Sensitivity and Specificity, Species Specificity


Check for Full Text / PubMed Unique Identifier (PMID): 16446034


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.